Ксилокаин

Quick links

Choose a section

Quick links to important sections

Advertisements

Ксилокаин

Advertisements
Advertisements
Advertisements

Overview of Ксилокаин

Quick Facts

Attribute Detail
Active Ingredient Lidocaine Hydrochloride
Drug Class Local Anesthetic; Class 1B Antiarrhythmic
Primary Use Local or regional anesthesia for procedures

Ксилокаин is a brand name for the medication lidocaine, an amide-type agent primarily used as a local anesthetic. Lidocaine works by stabilizing the neuronal membrane, which inhibits the necessary ionic fluxes required to initiate and conduct nerve impulses. This action effectively blocks the transmission of pain signals to the brain, producing a temporary numbing effect in the area where it is applied or injected.

Ксилокаин (Lidocaine Hydrochloride) is formulated for both local and regional anesthesia for various surgical, dental, or medical procedures. It is administered by a healthcare provider through different routes, including injection (infiltration or nerve block), as a topical solution, jelly, or patch applied to the skin or mucous membranes.

In addition to its use as a local anesthetic, lidocaine has a secondary function as a Class 1B antiarrhythmic agent. In this application, it is typically administered intravenously to treat acute ventricular arrhythmias (irregular heart rhythms) following conditions like myocardial infarction (heart attack) or certain toxic exposures. The dosage and administration route for lidocaine vary significantly depending on its intended use (anesthetic versus antiarrhythmic) and the specific condition being treated.

Advertisements

What side effects are possible with Ксилокаин?

Possible Side Effects and Safety Information

Ксилокаин (Lidocaine) primarily presents a safety profile characterized by the risk of Systemic Toxicity, which typically results from excessively high plasma concentrations, such as those caused by inadvertent intravascular injection or over-dosage. Adverse reactions are grouped by the affected System-Organ Class (SOC) and their frequency, as documented in regulatory sources.


Regulatory Classification of Adverse Reactions

The most significant reactions affect the Nervous System and the Cardiovascular System.

Frequency Examples of Adverse Reactions (Label-Documented)
Very Common Nausea, vomiting, dysphagia (difficulty swallowing).
Common Somnolence (drowsiness), dizziness, confusion, trembling, paraesthesia (tingling), blurred vision, hypotension (low blood pressure), bradycardia (slow heart rate).
Rare Anaphylactic reactions, convulsions (seizures), cardiac arrest, respiratory arrest, severe atrioventricular block.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions explicitly documented in official labeling include Cardiac Arrest, generalized Convulsions, and Methemoglobinemia (a rare blood disorder). The risk of these severe events is generally dose-related, meaning it increases when the drug's systemic blood level rises significantly. Repeated doses may lead to drug accumulation, increasing toxicity risk over time. Application to damaged or non-intact skin can also increase systemic absorption.

Population-Specific Safety: Dosage adjustments are officially required for older adults and patients with severe hepatic impairment due to reduced ability to metabolize the medicine. Caution is also advised for patients with pre-existing cardiac conduction disturbances.

Advertisements

Overdose and Emergency Response

Overdose Scope

Attribute Official Regulatory Statement
Documented overdose presentations Overdose manifests as a progression of Central Nervous System (CNS) effects potentially leading to cardiovascular depression.
Physiological systems affected Primarily affects the CNS and the Cardiovascular System.
Emergency-response statements Immediate medical attention is required upon the first appearance of signs of systemic toxicity. Resuscitative measures, including oxygen and necessary equipment, must be readily available.
When immediate medical help is required Seek immediate medical help if signs of systemic toxicity, such as lethargy, shallow breathing, or seizure activity, are observed.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Statement
Severity classification Systemic toxicity is defined by the progression from initial CNS signs to life-threatening respiratory arrest and cardiac arrest.
Population-specific notes Increased risk of toxicity is documented for elderly, acutely ill patients, and those with severe hepatic disease due to altered metabolism.

Official Overdose Statements

  • Overdose symptoms may begin with lightheadedness, nervousness, dizziness, tinnitus (ringing in the ears), and muscle tremors, which can progress to convulsions, unconsciousness, and respiratory depression.
  • Severe cardiovascular events include profound hypotension, bradycardia (slow heart rate), cardiac arrhythmias, and circulatory collapse.
  • No specific antidote is known for Lidocaine systemic toxicity; management focuses on continuous monitoring and supportive care to maintain the airway and circulation.

Connection to the overall overdose profile

Regulatory documents define the Lidocaine overdose profile as a dose-related progression of effects on the nervous and circulatory systems, which necessitates immediate action. The official guidance mandates seeking urgent medical help upon observing initial toxicity signs, as these can rapidly escalate to documented life-threatening events, including respiratory and cardiac arrest.

Advertisements

Therapeutic Uses of Ксилокаин

Ксилокаин (Xylocaine) is applied across domains where additional symptomatic support is needed for physical discomfort. The medication contributes to easing the overall symptom load and contributes to improved comfort during periods of heightened symptoms. It is relevant in contexts involving heightened systemic burden.


Supportive Symptom Management During Procedures

This domain is applicable within clinical settings that involve acute or temporary procedural discomfort. It is commonly used when short-term symptomatic assistance is needed to numb localized areas, such as before certain minor medical procedures. This application assists with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.


Temporary Relief for Skin and Mucous Membrane Discomfort

This cluster helps address symptom clusters that may appear suddenly or intensify temporarily, creating noticeable functional strain. The medicine is applied in addressing symptoms related to inflammatory or irritative states on the skin, in situations where patients experience localized discomfort, such as minor burns, insect bites, or abrasions. It supports the patient during difficult episodes by easing distress. It is also used in conditions presenting with systemic or localized discomfort, such as hemorrhoids and fissures.

Quick Fact: Supports the management of Localized Pain and Itching

Regulatory References

  1. Health Canada Product Monograph for Xylocaine Ointment 5%
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ксилокаин (Lidocaine)

This section outlines the population eligibility and non-eligibility for Lidocaine strictly based on official regulatory documentation.


Contraindicated Populations (Must Not Use)

Classification Condition or Population
Absolute Contraindication Known hypersensitivity to amide-type local anesthetics or any components.
Cardiovascular Exclusion Injectable antiarrhythmic use is contraindicated in Stokes-Adams syndrome, Wolff-Parkinson-White (WPW) syndrome, or severe heart block (without a pacemaker).

Populations Requiring Conditional Use

Eligibility is restricted for certain groups who face a higher risk of systemic toxicity:

  • Organ Function: Use with caution in patients with severe hepatic disease due to impaired drug clearance, and in those with severe renal dysfunction.
  • Age and Physical Status: Elderly, debilitated, or acutely ill patients are considered more sensitive and typically require reduced doses.
  • Pediatric Use: The safety and effectiveness of the systemic (antiarrhythmic) use has not been established in pediatric patients generally. Infants under 6 months of age are more susceptible to methemoglobinemia, a blood disorder.
  • Pregnancy/Lactation: Use during pregnancy is permitted only if clearly needed. Caution is advised when administering to a nursing mother.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ксилокаин (lidocaine) has an interaction profile characterized by documented effects on its metabolic clearance and potential for additive toxicities with certain medicine classes. These official interaction patterns are defined by regulatory agencies based on clinical and pharmacokinetic data.


Metabolic Clearance and Exposure

Interactions affecting lidocaine's clearance are commonly reported. Co-administration with substances that reduce hepatic blood flow, such as Cimetidine and certain Beta-blocking agents, may decrease the rate at which lidocaine is processed by the liver. This reduction in clearance can lead to increased plasma concentrations and a higher risk of systemic adverse reactions. Similarly, medicines that inhibit the CYP3A4 and CYP1A2 metabolic enzymes, including Amiodarone and some strong antifungal agents, are officially documented to significantly increase systemic exposure (AUC and Cmax) to lidocaine. Conversely, CYP1A2 inducers, such as compounds present in tobacco smoke, may reduce lidocaine blood levels.

Pharmacodynamic Effects

The toxic effects of lidocaine are additive with those of other local anesthetics and certain antiarrhythmic agents. Co-administration presents a potential for enhanced cardiovascular or neurological toxicity, and the total local anesthetic dose must be strictly considered. A further regulatory caution involves the co-administration of agents known to cause methemoglobinemia, as this combination increases the overall risk of developing that condition.

Population Considerations

Regulatory documents note that the elimination half-life of lidocaine may be prolonged in patients with liver dysfunction. This means that clearance-inhibiting interactions hold a greater clinical significance in this population, increasing the risk of accumulation and systemic toxicity.

Advertisements

Mechanism of Action

Ксилокаин ( Lidocaine) is an amide-type agent whose function stems from its ability to disrupt electrical signaling in excitable tissues through the targeted blockade of ion channels. This action engages two primary mechanistic domains: the peripheral nervous system to influence the conduction of sensory impulses and the cardiac conduction system to influence electrical excitability.

Targeted Blockade of Voltage-Gated Sodium Channels

This mechanism centers on the molecular interaction with voltage-gated sodium channels ( Na^+ channels), the primary molecular targets in both nerve and heart cells. By physically obstructing the channel pore from the cell's interior, the drug prevents the rapid influx of Na^+ ions required for cellular depolarization. This Na^+ channel blockade is use-dependent, meaning it preferentially binds to channels that are frequently opening and closing, a state common in rapidly depolarizing nerve fibers or in electrically hyperactive myocardial tissue.

Influence on Electrical Impulse Conduction

This action translates the molecular event into a physiological outcome by creating a conduction block in the peripheral nerves and a reduction in conduction velocity in the heart. In the nervous system, this interruption of the action potential along the nerve axon results in membrane stabilization, functionally silencing the transmission of electrical signals. The same mechanism in the heart influences automaticity and influences the uniformity of electrical signal propagation within the ventricles and Purkinje fibers.

Advertisements

Dosage and Administration Information

How to Use Ксилокаин

Ксилокаин (Lidocaine Hydrochloride) usage is strictly defined by regulatory guidelines, focusing on administration route, specific dosing ranges, and mandatory procedural conditions. The medicine is utilized in different forms for two primary purposes: local anesthesia and the acute management of ventricular arrhythmias.


Official Administration Guidelines

Parameter Instruction Principle
Route of Administration Administered via Intravenous (IV) injection for antiarrhythmic use, Parenteral Injection (e.g., nerve block, infiltration) for anesthesia, and Topical/Mucosal application.
Standard Adult Dosing Antiarrhythmic IV: Initial bolus of 50 mg to 100 mg, which may be repeated after 5 minutes, followed by a continuous infusion of 1 mg/min to 4 mg/min. Anesthetic Max Dose: Generally not to exceed 4.5 mg/kg or a total of 300 mg for a single intervention.
Frequency and Duration IV antiarrhythmic administration is limited to a total dose of 200 mg to 300 mg via bolus within one hour. Topical use is for temporary relief, typically applied up to 3 or 4 times daily or worn for a maximum of 12 hours within a 24-hour cycle for patches.

Population and Procedural Context

Official instructions mandate reduced doses for older adults and patients with impaired hepatic function due to altered drug metabolism. For anesthetic injections, aspiration for blood is required before and during administration to confirm correct placement. Furthermore, IV administration for arrhythmias must be conducted under continuous ECG monitoring to allow for immediate adjustment of the infusion rate, standardizing the acute management protocol.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Ксилокаин

Research evidence for Ксилокаин (lidocaine) describes its clinical evaluation in two primary roles: as a local anesthetic and as a medication for acute heart rhythm problems. The evidence base comprises a mix of Randomized Controlled Trials (RCTs) and systematic reviews. The overall evidence contributes to the broader research landscape regarding what has been observed in study groups, and does not provide guarantees for individual outcomes.


Evidence for use in Anesthesia for Procedures

Research exploring Lidocaine’s use for numbing a specific area is typically based on short-term RCTs focusing on procedures like dental work or minor surgery. Studies examined outcomes such as the achievement of anesthetic success and measured the time points related to the onset and duration of the anesthetic action. Data show patterns related to the rapid onset of localized anesthetic action, but follow-up durations were limited to the immediate acute period (minutes to hours).


Evidence for Topical Relief of Localized Pain

For ongoing, localized discomfort, evidence includes double-blind, placebo-controlled RCTs exploring topical and transdermal formulations. These studies monitored patient-reported outcomes over defined time intervals, often several weeks to a few months. Trials reported various changes in pain scale scores from the baseline measurement. However, data on long-term functional outcomes persisting beyond the study duration is generally limited.


Evidence for Treatment of Acute Heart Rhythms

For its antiarrhythmic role, intravenous Lidocaine was evaluated in critical care settings through large-scale RCTs. Studies monitored critical outcomes including survival to hospital discharge and the return of spontaneous circulation (ROSC). Data show patterns related to survival outcomes that were highly dependent on the timing of administration and the specific patient subgroup; studies observed that findings regarding overall survival to hospital discharge were variable. For this use, the certainty remains low regarding sustained changes in overall survival.

Key Studies & References Xylocaine 5% Ointment Patient Medication Information (Health Canada Monograph)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ксилокаин (FAQ)


Q: Is Ксилокаин the same as lidocaine?

Ксилокаин is a brand name for the generic active ingredient, lidocaine hydrochloride. In regulatory documents and medical settings, the terms often refer to the same medication, which is an amide-type local anesthetic used to block nerve signals.


Q: What are the different forms of Ксилокаин available (ointment, jelly, injection, etc.)?

Official product information indicates that lidocaine is manufactured in several different forms to suit various medical needs. These include solutions for injection (used for local anesthesia and cardiac issues) and various topical products such as creams, ointments, gels, and patches.


Q: What kind of minor pain or skin irritation is Ксилокаин used to relieve?

Topical formulations of lidocaine are officially indicated for the temporary relief of pain and discomfort associated with various minor skin irritations. This typically includes minor cuts, scrapes, minor burns, and general skin soreness.


Q: Is Ксилокаин a narcotic or addictive pain medication?

No, according to its official classification, lidocaine is a local anesthetic agent. It is not classified as a narcotic or controlled substance and is not considered to be an addictive pain medication in the same way as opioids.


Q: Can Ксилокаин be used for pain relief from minor burns or sunburn?

Yes, regulatory documents confirm that topical lidocaine is indicated for the temporary relief of pain and itching caused by both minor burns and sunburn. It works by numbing the nerve endings in the affected skin area.


Q: Is Ксилокаин safe to use on insect bites or stings?

Official labeling for topical formulations includes the indication for the temporary relief of pain and itching caused by insect bites. It is important to note that the product is intended only for minor irritation and not severe allergic reactions.


Q: Does Ксилокаин help with the pain and discomfort of hemorrhoids or anal fissures?

Yes, specific formulations, such as lidocaine rectal cream, are officially indicated for the relief of pain, soreness, and discomfort caused by hemorrhoids and anal fissures. These products provide localized pain relief.


Q: Is it common for there to be a slight burning or stinging sensation when applying Ксилокаин?

Official safety information documents that a sensation of burning or stinging at the site of application is a documented and often common reaction when using topical lidocaine. This localized discomfort is generally temporary.


Q: Can Ксилокаин be used safely while breastfeeding or pregnant?

Regulatory-affiliated safety guidance suggests that topical lidocaine is considered generally safe for use during both pregnancy and breastfeeding. Because the amount of drug transferred into breast milk is considered low, the risk of side effects for the baby is considered small.


Q: Is it normal to feel dizzy or light-headed after using a large area of topical Ксилокаин?

Dizziness and light-headedness are documented signs of systemic exposure to lidocaine, meaning the drug has been absorbed into the bloodstream. The risk of these Central Nervous System (CNS) effects is higher when the drug is applied over large or damaged areas of skin, leading to increased absorption.


Q: What is the difference between Ксилокаин and other topical numbing creams or ointments?

Lidocaine is officially classified as an amide-type local anesthetic that works by blocking sodium channels. Other numbing creams may use lidocaine itself, other amide-type agents, or a different chemical class (such as esters), each having slightly different characteristics and uses.


Q: What are the main differences between the Xylocaine ointment and the Xylocaine jelly formulations?

While both provide topical numbing, they have different primary official uses. Lidocaine jelly is specifically formulated and indicated as an anesthetic lubricant for medical procedures, such as intubation or catheter insertion. The ointment is typically indicated for general surface pain relief.


Q: Is Ксилокаин effective for managing nerve pain like post-herpetic neuralgia (pain after shingles)?

Yes, specific, higher-concentration products, such as the 5% lidocaine patch, are formally indicated for the relief of pain associated with Post-Herpetic Neuralgia (PHN). This is a severe, chronic nerve pain that can occur after a shingles outbreak.


Q: Can Ксилокаин be used as a topical anesthetic before medical procedures like IV insertion or blood draws?

Topical lidocaine is used in clinical settings to help numb the skin before minor procedures such as starting an IV or taking blood. This provides localized numbing at the injection site.


Q: Is it generally safe to drive or operate machinery after using Ксилокаин?

Official labels caution that depending on the method and area of administration, lidocaine may affect the ability to drive or operate machinery. If side effects such as dizziness or drowsiness occur due to systemic absorption, operating machinery or driving is not recommended.


Q: Is there a difference in how long different concentrations of Ксилокаин injection last?

Yes, official medical principles state that the duration of the anesthetic effect is known to be dose- and concentration-dependent. A solution with a higher concentration of lidocaine will generally provide a more intense, localized, and sometimes longer-lasting anesthetic effect.


Q: What is the connection between Ксилокаин and cimetidine (a medicine for reflux)?

Cimetidine is officially documented to interact with lidocaine because it inhibits the enzymes that break the drug down in the liver. This can slow down the clearance of lidocaine from the body, leading to potentially increased blood concentrations and a higher risk of systemic side effects.


Q: Can Ксилокаин cause temporary issues with swallowing when used in the throat area?

Yes. When lidocaine products are used in the mouth or throat, they are intended to temporarily numb the area. This local numbing action can cause dysphagia (difficulty swallowing), which is documented as a very common, but temporary, adverse reaction.


Q: Why is a healthcare professional's guidance needed for using Ксилокаин in infants or young children?

Official warnings state that the risk of severe adverse events and side effects is higher in children, especially those under 3 years old, when lidocaine is used improperly. Due to the heightened risk of toxicity, official warnings state that healthcare professional guidance is essential to ensure correct usage and appropriate, reduced dosing.


Q: Is it safe to use other skin products, like moisturizers, over the area where Ксилокаин was applied?

Regulatory-affiliated guidance suggests that consulting with a healthcare provider is recommended before applying other products, such as moisturizers, over the treated area. This is to avoid potential interactions or unintended increases in drug absorption.


Q: What happens if topical Ксилокаин gets accidentally rubbed into the eyes?

Official safety guidance advises flushing the eyes with water as a precaution. Medical attention is recommended if irritation develops or persists.


Q: Is the sensation of numbness from Ксилокаин different from a 'pins and needles' feeling?

Yes, they are generally considered different. The intended effect is numbness (loss of sensation). However, official labels list paresthesia (which can be felt as a tingling or 'pins and needles' sensation) as a common central nervous system side effect, which is distinct from the primary goal of pain relief.


Q: How does the body eliminate or break down Ксилокаин after it has been used?

According to the pharmacokinetics section of the label, lidocaine is primarily rapidly metabolized (broken down) by the liver into other compounds. These metabolites, along with a small amount of the unchanged drug, are then mainly excreted by the kidneys.


Q: Is it true that different formulations of Ксилокаин have different uses (e.g., jelly for lubrication/procedures)?

Yes, the official indications for use vary by formulation. For example, the jelly is specifically indicated as an anesthetic lubricant for specific procedures, whereas the cream or ointment has indications for general skin surface pain relief.


Q: Why are people with G6PD deficiency at a higher risk for certain side effects with Ксилокаин?

Official warnings note that individuals with a condition called Glucose-6-phosphate dehydrogenase (G6PD) deficiency are at an increased risk of developing methemoglobinemia when using lidocaine. This is a serious blood disorder documented as a rare adverse reaction.


Q: How long after using Ксилокаин is it safe to resume normal activities like eating or chewing?

For products used in the mouth or throat, official guidance commonly cites a waiting period of at least 60 minutes (1 hour) before resuming normal activities like eating or chewing. This period helps minimize the risk of accidental injury or choking while the area is still numb.


Q: What precautions should be taken if a patient is taking seizure or epilepsy medication while using Ксилокаин?

Official information indicates that lidocaine can interact with certain anti-seizure medications, such as phenytoin. Additionally, high levels of lidocaine are linked to a risk of convulsions. These potential interactions and risks mean that the concurrent use of these medicines requires careful medical supervision.

Advertisements

How should Ксилокаин be stored and disposed of?

How to Store and Dispose of Ксилокаин?

This section details the official storage, handling, and disposal requirements as mandated by regulatory documents for Lidocaine Hydrochloride (Ксилокаин).

Official Storage and Handling

Requirement Details
Temperature Store at Controlled Room Temperature (20 C to 25 C), protecting the solution from freezing (must not be exposed to temperatures below 15 C).
Container Integrity The solution must be visually inspected before administration; do not use if it appears discolored or contains particulate matter.
In-Use Stability Unused portions of single-dose, preservative-free formulations must be discarded immediately after the initial use.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Expired or unused Ксилокаин products must be disposed of according to local pharmaceutical waste regulations. To prevent environmental contamination, the medication must not be flushed down the toilet or poured into a household drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ксилокаин found in:

A-Z Index: